- Details
- Lauren Harshman, MD, Alicia Morgans, MD and Toni Choueiri, MD discuss combination therapy for the management of metastatic kidney cancer with the recent approval of pembrolizumab plus axitinib. The combination was approved for all patients regardless of risk category. This adds to the treatment armamentarium for metastatic kidney cancer with the already approved nivolumab plus ipilimumab regimen....
|
- Details
- Nick Vogelzang discusses a brief history of the advancements in treating prostate cancer. He provides background on how we have arrived at where we are now with the advances in both the diagnosis and treatment of prostate cancer while talking with Alicia Morgans. Dr. Vogelzang reflects upon the time when we were relegated to using primitive bone scans to define disease to the current era of advanc...
|
- Details
- Evan Yu and Alicia Morgans share in a discussion on where we are in understanding treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) and sequencing treatments after progression from nmCPRC to mCRPC. The conversation includes selecting and evaluating patients with mCRPC and how treatments are selected for these patients. Dr. Yu discusses the opportunities to individualize tr...
|
- Details
- Anne Cameron, MD, discusses the use of gentamicin bladder irrigation for the prevention of symptomatic urinary tract infections (UTIs) in neurogenic bladder patients with intermittent catheterization. Gentamicin is not absorbed through the bladder, therefore, there are no concerns with the development of antibiotic resistance or potential toxicity. Dr. Cameron reviews the protocol for gentamicin i...
|
- Details
- Neal Shore and colleague, Jonathan Rubenstein provide an update on the advances and developments that have been communicated in regards to the truly important challenge of BCG shortage for the use of patients with a high-risk non-muscle invasive bladder cancer. This is an international problem. In a previous program Neal Shore, Ashish Kamat, and Jonathan Rubenstein talked about alternative dosing...
|
- Details
- Dan George concentrated on the patient experience in the treatment of metastatic castration-resistant prostate cancer (mCRPC). He described a typical treatment timeline where a new patient presents with elevated PSA is initially treated with androgen deprivation therapy (ADP) to reduce testosterone feeding tumor growth. While the patient may initially respond with a reduced PSA, it is most common...
|
- Details
- Phillip Koo welcomes Bital Savir-Baruch who is presenting a review of prostate cancer imaging with 18F-FACBC fluciclovine (Axumin®) in men with suspected prostate cancer recurrence. Dr. Baruch reviews the benefits of this technology including earlier detection of recurrent disease as compared to conventional imaging, inability of the tracer to be metabolized and the slow urinary excretion. While d...
|
- Details
- Kelvin Moses explores the clinical benefit of sipuleucel-T treatment in African American men with advanced prostate cancer in this conversation with Alicia Morgans. A large volume of evidence has demonstrated that African American men have an increased risk of developing mCRPC and have higher mortality as compared with Caucasian men. Sipuleucel-T has demonstrated a survival benefit in men with met...
|
- Details
- Jens Bedke enthusiastically discusses the transformation in first-line treatment of RCC from monotherapy, which has been the standard of care on the treatment of RCC to now combination therapies. The first-line therapy with a combination of an immune checkpoint inhibitor and a tyrosine kinase inhibitor (TKI) improved outcomes in patients with clear-cell metastatic renal cell carcinoma (mRCC), as c...
|
- Details
- Thomas Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium with Charles Ryan. The checkpoint inhibitor pembrolizumab plus the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor axitinib significantly improved overall survival, progression-free survival, and objective response rates vs sunitinib as first-line therapy...
|
